{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T08:22:30Z","timestamp":1795162950150,"version":"4.10.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Farma S.p.A. Origgio (VA), Italy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Biologics have demonstrated efficacy in PsA in randomized clinical trials. More evidence is needed on their effectiveness under real clinical practice conditions. The aim of the present work is to provide real-world evidence of the effectiveness of biologics for PsA in the daily clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>CHRONOS was a multicenter, non-interventional, cohort study conducted in 20 Italian hospital rheumatology clinics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>399 patients were eligible (56.9% females, mean (SD) age: 52.4 (11.6) years). The mean (SD) duration of PsA and psoriasis was 7.2 (6.9) and 15.3 (12.2) years, respectively. The mean (SD) duration of the biologic treatment under analysis was 18.6 (6.5) months. The most frequently prescribed biologic was secukinumab (40.4%), followed by adalimumab (17.8%) and etanercept (16.5%). The proportion of overall responders according to EULAR DAS28 criteria was 71.8% (95% CI: 66.7\u201376.8%) out of 308 patients at 6\u00a0months and 68.0% (95% CI: 62.7\u201373.3%) out of 297 patients at 1\u00a0year. Overall, ACR20\/50\/70 responses at 6\u00a0months were 41.2% (80\/194), 29.4% (57\/194), 17.1% (34\/199) and at 1-year were 34.9% (66\/189), 26.7% (51\/191), 18.4% (36\/196), respectively. Secondary outcome measures improved rapidly already at 6\u00a0months: mean (SD) PASI, available for 87 patients, decreased from 3.2 (5.1) to 0.6 (1.3), the proportion of patients with dactylitis from 23.6% (35\/148) to 3.5% (5\/142) and those with enthesitis from 33.3% (49\/147) to 9.0% (12\/133).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The CHRONOS study provides real-world evidence of the effectiveness of biologics in PsA in the Italian rheumatological practice, confirming the efficacy reported in RCTs across various outcome measures.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41927-022-00284-w","type":"journal-article","created":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T23:03:58Z","timestamp":1662937438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study"],"prefix":"10.1186","volume":"6","author":[{"given":"Delia","family":"Colombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol","family":"Frassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Pagano Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lomater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Del Medico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Limonta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Raffeiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Daniela","family":"Grembiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Tirri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Carlo","family":"Sarzi Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Simoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Orsenigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Zagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and the CHRONOS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol","family":"Frassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Caminiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lomater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Del Medico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Limonta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Raffeiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Daniela","family":"Grembiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Tirri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Carlo Sarzi","family":"Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"issue":"12","key":"284_CR1","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ncprheum0670","volume":"3","author":"C Ritchlin","year":"2007","unstructured":"Ritchlin C. Psoriatic disease\u2014from skin to bone. Nat Clin Pract Rheumatol. 2007;3(12):698\u2013706.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"284_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaut.2016.12.002","volume":"78","author":"RA Pollock","year":"2017","unstructured":"Pollock RA, Abji F, Gladman DD. Epigenetics of psoriatic disease: a systematic review and critical appraisal. J Autoimmun. 2017;78:29\u201338.","journal-title":"J Autoimmun"},{"issue":"10","key":"284_CR3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"1","key":"284_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65\u201370.","journal-title":"Clin Med (Lond)"},{"issue":"1","key":"284_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.23789","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken). 2019;71(1):2\u201329.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"284_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4081\/reumatismo.2012.66","volume":"64","author":"M Catanoso","year":"2012","unstructured":"Catanoso M, Pipitone N, Salvarani C. Epidemiology of psoriatic arthritis. Reumatismo. 2012;64:66\u201370.","journal-title":"Reumatismo"},{"key":"284_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, Khraishi MM, Tha\u00e7i D, Behrens F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729\u201335.","journal-title":"J Am Acad Dermatol"},{"key":"284_CR8","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1136\/annrheumdis-2014-205490","volume":"73","author":"E Lie","year":"2014","unstructured":"Lie E, Fagerli KM, Mikkelsen K, Rodevand E, Lexberg A, Kalstad S, et al. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002\u20132011: data from the NOR-DMARD register. Ann Rheum Dis. 2014;73:1905\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"284_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11926-018-0746-0","volume":"20","author":"O Elalouf","year":"2018","unstructured":"Elalouf O, Chandran V. Novel therapeutics in psoriatic arthritis. What is in the pipeline? Curr Rheumatol Rep. 2018;20(7):36.","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"284_CR10","first-page":"1251","volume":"56","author":"LC Coates","year":"2017","unstructured":"Coates LC, Gossec L, Ramiro S, Mease P, van der Heijde D, Smolen JS, et al. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology (Oxford). 2017;56(8):1251\u20133.","journal-title":"Rheumatology (Oxford)"},{"key":"284_CR11","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1517\/14712598.2014.967211","volume":"14","author":"RJ Lories","year":"2014","unstructured":"Lories RJ, deVlam K. Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity. Expert Opin Biol Ther. 2014;14:1825\u201336.","journal-title":"Expert Opin Biol Ther"},{"key":"284_CR12","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/acr.22645","volume":"67","author":"A Kavanaugh","year":"2015","unstructured":"Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res (Hoboken). 2015;67:1739\u201349.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"284_CR13","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137\u201346.","journal-title":"Lancet"},{"issue":"1","key":"284_CR14","doi-asserted-by":"publisher","first-page":"e000942","DOI":"10.1136\/rmdopen-2019-000942","volume":"5","author":"JR Curtis","year":"2019","unstructured":"Curtis JR, Mariette X, Gaujoux-Viala C, Blauvelt A, Kvien TK, Sandborn WJ, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019;5(1):e000942.","journal-title":"RMD Open"},{"issue":"11","key":"284_CR15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/1744666X.2018.1524755","volume":"14","author":"TJ Love","year":"2018","unstructured":"Love TJ, Kavanaugh A. Golimumab in the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(11):893\u20138.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"284_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"key":"284_CR17","unstructured":"DAS28-EULAR Response criteria [online] Available at: [Accessed September, 2020]."},{"key":"284_CR18","doi-asserted-by":"publisher","first-page":"528105","DOI":"10.1155\/2014\/528105","volume":"2014","author":"F Salaffi","year":"2014","unstructured":"Salaffi F, Ciapetti A, Carotti M, Gasparini S, Gutierrez M. Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int. 2014;2014:528105.","journal-title":"Biomed Res Int"},{"key":"284_CR19","first-page":"353657","volume":"2015","author":"P Naranje","year":"2015","unstructured":"Naranje P, Prakash M, Sharma A, Dogra S, Khandelwal N. Ultrasound findings in hand joints involvement in patients with psoriatic arthritis and its correlation with clinical DAS28 score. Radiol Res Pract. 2015;2015:353657.","journal-title":"Radiol Res Pract"},{"issue":"5","key":"284_CR20","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","volume":"77","author":"P Nash","year":"2018","unstructured":"Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, G\u00f3mez-Reino JJ, Aelion JA. ACTIVE investigators. Early and sustained efficacy with apremilast monotherapy in biological-na\u00efve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis. 2018;77(5):690\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"284_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40257-019-00490-2","volume":"21","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi A, Burlando M, Caldarola G, Conti A, Damiani G, De Simone C, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2020;21(3):441\u20137.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"284_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van \u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44\u20138.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"284_CR23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.1780360601","volume":"36","author":"DT Felson","year":"1993","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum. 1993;36(6):729\u201340.","journal-title":"Arthritis Rheum"},{"key":"284_CR24","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. For the FUTURE 1 Study Group. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329\u201339.","journal-title":"N Engl J Med"},{"key":"284_CR25","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. On behalf of the FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137\u201346.","journal-title":"Lancet"},{"issue":"3","key":"284_CR26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/acr.23111","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, et al. For the FUTURE-1 Study Group. Secukinumab for long-term treatment of psoriatic arthritis: a two-year follow up from a phase III, randomized, Double-Blind Placebo-Controlled Study. Arthritis Care Res. 2017;69(3):347\u201355.","journal-title":"Arthritis Care Res"},{"issue":"10230","key":"284_CR27","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. DISCOVER-2 Study Group. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126\u201336.","journal-title":"Lancet"},{"key":"284_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137\u201345.","journal-title":"Arthritis Rheum"},{"key":"284_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl 1","key":"284_CR30","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1111\/j.1524-4733.2005.00066.x","volume":"8","author":"M Atkinson","year":"2005","unstructured":"Atkinson M, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health. 2005;8(Suppl 1):S9\u201324.","journal-title":"Value Health"},{"key":"284_CR31","doi-asserted-by":"publisher","first-page":"R72","DOI":"10.1186\/ar1941","volume":"8","author":"L Carmona","year":"2006","unstructured":"Carmona L, G\u00f3mez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8:R72.","journal-title":"Arthritis Res Ther"},{"key":"284_CR32","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/art.30117","volume":"63","author":"B Glintborg","year":"2011","unstructured":"Glintborg B, \u00d8stergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63:382\u201390.","journal-title":"Arthritis Rheum"},{"key":"284_CR33","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/ard.2007.073544","volume":"67","author":"LE Kristensen","year":"2008","unstructured":"Kristensen LE, G\u00fclfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis. 2008;67:364\u20139.","journal-title":"Ann Rheum Dis"},{"key":"284_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/art.23333","volume":"59","author":"MS Heiberg","year":"2008","unstructured":"Heiberg MS, Koldingsnes W, Mikkelsen K, R\u00f8devand E, Kaufmann C, Mowinckel P, et al. The comparative one-year performance of anti-turmor necrosis factor \u03b1 drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Care Res. 2008;59:234\u201340.","journal-title":"Arthritis Care Res"},{"key":"284_CR35","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/ar2670","volume":"11","author":"AA Saad","year":"2009","unstructured":"Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DPM. Persistence with antitumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:R52.","journal-title":"Arthritis Res Ther"},{"key":"284_CR36","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/rheumatology\/kep423","volume":"49","author":"AA Saad","year":"2010","unstructured":"Saad AA, Ashcroft DM, Watson KD, Symmons DPM, Noyce PR, Hyrich KL. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register: reply. Rheumatology. 2010;49:697\u2013705.","journal-title":"Rheumatology"},{"key":"284_CR37","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.3899\/jrheum.091477","volume":"37","author":"LM Virkki","year":"2010","unstructured":"Virkki LM, Sumathikutty BC, Aarnio M, Valleala H, Heikkil\u00e4 R, Kauppi M, et al. Biological therapy for psoriatic arthritis in clinical practice: outcomes up to 2 years. J Rheumatol. 2010;37:2362\u20138.","journal-title":"J Rheumatol"},{"key":"284_CR38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","volume":"73","author":"KM Fagerli","year":"2014","unstructured":"Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, R\u00f8devand E, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis. 2014;73:132\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"284_CR39","doi-asserted-by":"publisher","first-page":"e000723","DOI":"10.1136\/rmdopen-2018-000723","volume":"4","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. 2018;4(2):e000723.","journal-title":"RMD Open"},{"issue":"1","key":"284_CR40","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-018-1773-y","volume":"20","author":"LC Coates","year":"2018","unstructured":"Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, et al. FUTURE 2 study group. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Res Ther. 2018;20(1):272.","journal-title":"Arthritis Res Ther"},{"key":"284_CR41","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279\u201389.","journal-title":"Arthritis Rheum"},{"key":"284_CR42","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264\u201372.","journal-title":"Arthritis Rheum"},{"issue":"9227","key":"284_CR43","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385\u201390.","journal-title":"Lancet"},{"issue":"6","key":"284_CR44","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/bjd.17849","volume":"181","author":"ZZN Yiu","year":"2019","unstructured":"Yiu ZZN, Mason KJ, Barker JNWN, Hampton PJ, McElhone K, Smith CH, et al. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. Br J Dermatol. 2019;181(6):1265\u201371.","journal-title":"Br J Dermatol"},{"issue":"5","key":"284_CR45","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1468-3083.2012.04496.x","volume":"27","author":"PP van L\u00fcmig","year":"2013","unstructured":"van L\u00fcmig PP, van de Kerkhof PC, Boezeman JB, Driessen RJ, de Jong EM. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive vs. non-naive patients. J Eur Acad Dermatol Venereol. 2013;27(5):593\u2013600.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"284_CR46","first-page":"1","volume":"23","author":"E Zagni","year":"2020","unstructured":"Zagni E, Colombo D, Fiocchi M, Perrone V, Sangiorgi D, Andretta M. Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting. Expert Rev Pharmacoecon Outcomes Res. 2020;23:1\u20137.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"284_CR47","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jbspin.2018.03.007","volume":"86","author":"J Shan","year":"2019","unstructured":"Shan J, Zhang J. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Joint Bone Spine. 2019;86(2):173\u201383.","journal-title":"Joint Bone Spine"},{"issue":"12","key":"284_CR48","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1007\/s10067-018-4227-7","volume":"37","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clin Rheumatol. 2018;37(12):3285\u201396.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"284_CR49","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3109\/09546634.2012.755255","volume":"24","author":"M Bonafede","year":"2013","unstructured":"Bonafede M, Johnson BH, Fox KM, Watson C, Gandra SR. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatolog Treat. 2013;24(5):369\u201373.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"284_CR50","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3899\/jrheum.151042","volume":"43","author":"F Iannone","year":"2016","unstructured":"Iannone F, Lopriore S, Bucci R, Lopalco G, Chial\u00e0 A, Cantarini L, Lapadula G. Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings. J Rheumatol. 2016;43(5):911\u20137.","journal-title":"J Rheumatol"},{"issue":"2","key":"284_CR51","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/bjd.18981","volume":"183","author":"ZZN Yiu","year":"2020","unstructured":"Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. BADBIR Study Group. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183(2):294\u2013302.","journal-title":"Br J Dermatol"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-022-00284-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-022-00284-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-022-00284-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T23:04:30Z","timestamp":1662937470000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-022-00284-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["284"],"URL":"https:\/\/doi.org\/10.1186\/s41927-022-00284-w","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"8 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the amended Declaration of Helsinki. Ethical approvals for this study was obtained from each participating site according to Italian Regulation applicable for prospective observational studies. The patients provided written informed consent before the data collection. The study was approved by the Ethic Committee of the coordinating center (A.O.U. Policlinico-Vittorio Emanuele P.O. San Marco, Catania, Italy) and then by the Ethic Committees of all the participating centers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DC was a part-time employee of Novartis Farma Italy when the study was conducted. AM has received honoraria and speaker fees from Abbvie, Amgen, Eli-Lilly, Novartis, Pfizer, Janssen, and UCB. AO is employee of MediNeos Observational Research (Modena, Italy), hired by Novartis Farma Italy, responsible for the design and conduction of the CHRONOS study, as well as scientific support, clinical operations, data management, statistical analysis. LS is employee of MediNeos Observational Research (Modena, Italy), hired by Novartis Farma Italy, responsible for the design and conduction of the CHRONOS study, as well as scientific support, clinical operations, data management, statistical analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}